A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors With Mutant KRAS
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2016
At a glance
- Drugs Cobimetinib (Primary) ; Duligotuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 14 Jul 2016 Status changed from recruiting to completed.
- 02 Jun 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.
- 02 Jun 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.